FDA approves Atebrioz for FOP, adding Mirum's fourth commercial medicine

Upcoming catalystiThe event that could move the share price.

The FDA approved zilurgisertib under the brand name Atebrioz on 25 September 2026 at about 19:00 UTC for patients aged 12 and older with fibrodysplasia ossificans progressiva. Mirum expects to launch the once-daily 100 mg tablet in the United States in October 2026. The regulatory event is complete.

Main stock affectediThe company the event affects most directly.

Mirum Pharmaceuticals, ticker MIRM.

Current priceiWhere the shares traded when this write-up was made, and when that was.

$97.00 as of 31 Aug 2026, 14:41 UTC.

Expected stock reactioniWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.

Positive. Approval adds a fourth commercial medicine and removes the card's main regulatory uncertainty. The size and durability of the reaction now depend on the label, launch execution, pricing and competition in the small FOP market.

Action before the eventiWhat we suggest you do before the event. Buy, Watch or Avoid.

The pre-event setup is complete. The FDA outcome is known, so the remaining assessment is the market response to the approved label and the October launch rather than the former risk of a Complete Response Letter.

Why the stock is affectediThe link between the event and this company.

Mirum owns worldwide commercialization rights to zilurgisertib. Approval lets it launch an oral FOP treatment in October 2026, creating a new revenue stream, diversifying the company beyond liver medicines and validating its expansion into rare genetic diseases. Mirum must pay Incyte regulatory and sales milestones plus mid-to-high single-digit royalties, so it will not keep all future revenue.

Catalyst confidenceiHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.

The FDA approved Atebrioz on 25 September 2026. Confidence in the regulatory outcome is now 100%; the remaining uncertainty concerns commercial uptake rather than approval.

Stock-reaction confidenceiHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.

Moderate, 62%. Approval should be positive, but the size of the reaction depends on the label, safety language, launch pricing, and how investors assess competition from Regeneron's Pasatru.

When the market will reactiThe moment the price is likely to move, such as at the announcement or at the next market open.

The approval became public at about 19:00 UTC on Friday 25 September 2026, during the final hour of regular US trading, so the first reaction began immediately. Price discovery can continue in the regular session on Monday 28 September as analysts assess the label, competition and October launch.

Effect on the businessiWhat the event changes for the company itself, such as its sales, costs or profit.

Approval gives Mirum a fourth commercial product and an entry into FOP. The immediate 2026 revenue effect should be limited because the US launch is planned for October and the diagnosed population is small, about 300 patients in the United States and 900 worldwide. The larger effect is on pipeline credibility and long-term valuation, while royalties and milestone payments owed to Incyte reduce the profit contribution.

Market expectations and forecastiWhat investors already expect from this event, and the numbers being forecast.

The FDA granted full approval for patients aged 12 and older and Mirum named an October US launch, resolving the label and timing questions that mattered most before the decision. The remaining debate is commercial: how quickly doctors adopt an oral treatment in a small population, what it costs, and how it competes with Regeneron's Pasatru and Ipsen's Sohonos. The positive regulatory outcome supports the card's positive direction, while the small market can restrain the size of the re-rating.

How much is already priced iniHow much of the expected outcome the share price already reflects before the event happens.

Medium. Investors have known the Priority Review date, positive lesion-volume data, and planned year-end launch for months. The stock also remains about 25% below its 9 July 2026 52-week high of $130.00, showing that the market is not pricing a perfect outcome. October options price a large event move, which confirms that uncertainty remains expensive.

Expected price move and durationiHow far the share price may move because of this event, and how long that move may last.

Options-Implied Move The latest reliable event-covering options snapshot I could confirm showed an implied move of ±22.1% for the 16 October 2026 expiration. The ± sign measures expected size, not direction. Options are not taking the positive side of this report. The snapshot was based on the 26 August 2026 close, so live pricing should be checked before trading. Historical Event Analysis Mirum received FDA approval for LIVMARLI in PFIC on 13 March 2024, a further LIVMARLI age expansion on 24 July 2024, and CTEXLI approval on 21 February 2025. These were useful business milestones, but they are not close enough to the present setup. Zilurgisertib is an in-licensed product, faces newly approved competition, and is supported by a trial whose primary analysis did not reach conventional statistical significance. I cannot confirm reliable, adjustment-consistent event-window price moves for these historical dates. Historical Average Move The historical sample is too limited and insufficiently comparable to calculate a reliable average. No historical average is used in the trade estimate. Our Expected Move +8% to +15% on approval. This is below the ±22.1% options-implied move because Mirum already has three approved medicines, the FOP population is small, and Regeneron has an approved competitor. It is still large enough to reflect approval of a new commercial product and removal of regulatory uncertainty. Impact Strength High. The decision is binary, changes the number of products Mirum can sell, and tests the company's strategy of building a broader rare-disease portfolio. Estimated Duration Several weeks. The first move should occur within one to three trading days. A clean label, credible pricing, and a firm launch schedule could create a longer repricing. A vague label or cautious launch guidance could cause the initial gain to fade.

Result needed for a big moveiWhat the outcome has to be for the stock to move a lot instead of a little.

The regulatory half of the positive case occurred: full approval for patients aged 12 and older and an October launch plan. A larger and more durable move now requires credible pricing, manageable safety monitoring and evidence that doctors can identify and start enough patients to make the small FOP market commercially meaningful.

Possible outcomesiThe main ways the event could turn out, with the expected stock reaction for each one.

The regulatory outcome is the positive scenario: full approval for patients aged 12 and older with an October US launch planned. The remaining positive case is rapid adoption and manageable monitoring; the neutral case is a slow launch in the small diagnosed population; the negative case is weak uptake, payer resistance or stronger competition despite approval.

Other affected stocksiOther companies that could move on the same news, such as suppliers and competitors.

INCY could receive regulatory milestones and future royalties. The effect should be small relative to Incyte's total business. REGN could face a new oral competitor to its recently approved FOP medicine, Pasatru.

What the market may be missingiSomething we think investors have overlooked or read wrong.

Regeneron's Pasatru approval still cuts both ways. It validates reduction in new heterotopic bone formation as a treatment benefit in FOP, but it also gives Atebrioz an approved competitor. Atebrioz's once-daily oral dosing may be convenient; the question the market must now answer is whether that advantage supports meaningful uptake in a very small patient population.

What else lands that dayiOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.

The FDA approval arrived at about 19:00 UTC on Friday 25 September 2026, after durable-goods orders and the final Michigan consumer survey had already been published. Those releases are immaterial to this small biotechnology company. The first full session after the approval is Monday 28 September, when only minor regional surveys share the calendar, so company-specific interpretation should dominate.

Main risksiWhat could go wrong, and what would prove this call wrong.

The main risks are now low commercial uptake, payer resistance, a smaller-than-expected addressable population, safety monitoring and competition from Pasatru and Sohonos. The regulatory rejection risk has been removed, but launch execution and the small FOP market keep overall event risk at medium.

Other factorsiAnything else worth knowing that the sections above do not cover.

Short interest was about 10% of shares outstanding in the latest confirmed data. A clean approval could force some short covering and amplify the initial rise. High institutional ownership can also produce a sharp move if large funds reach the same conclusion at once.

Trend over 6 to 12 monthsiWhich way the share price has been heading over the past year, and how far it has travelled.

The six-month trend is slightly positive, but uneven. The stock gained about 5.6% from 27 February through 28 August 2026. Its six-month low was approximately $84.33 on 9 March 2026, and its high was $130.00 on 9 July 2026. Over 52 weeks, the stock was up about 30.6%. The 52-week low was $63.23 on 15 December 2025.

Recent price actioniWhat the shares have done over the last few weeks and sessions, and on what kind of volume.

MIRM fell from $105.95 on 31 July to $97.46 on 28 August, a decline of 8.0%. It dropped 11.0% on 6 August after quarterly results and the delayed volixibat filing timetable, on volume of about 2.97 million shares. It recovered 6.9% on 7 August. From 24 August through 28 August, it gained about 0.8%. At $97.00, the stock sits close to the middle of its $63.23 to $130.00 52-week range.

Market structureiThe shape of the chart. Rising highs and rising lows mean an uptrend, falling ones mean a downtrend, and neither means the price is stuck in a range.

The long-term advance has been interrupted by a correction from $130.00. The current chart is building a range between roughly $89 and $102. In simple terms, buyers have appeared near $90 to $95, while sellers repeatedly appear near $100 to $102.

Support and resistance zonesiPrice areas where buyers have stepped in before, and price areas where sellers have. They often slow the price down when it gets there again.

First support is $95 to $97. This zone was tested repeatedly during August, including around 20, 21, 24, 25, 26 and 28 August. A close below $95 would expose $89 to $94, the earnings-reaction zone tested on 6 and 7 August. A close below $88.88 would confirm a deeper breakdown. First resistance is $100 to $102, tested numerous times during August. A strong close above $102 could open a move toward $105 to $107. The major resistance zone is $112 to $116, tested repeatedly in late July. A close above $116 would repair much of the recent technical damage.

50-day and 200-day moving averagesiThe average closing price over the last 50 days and the last 200 days. Where the price sits against them shows whether the recent trend is strong or fading.

The confirmed 50-day moving average was $110.27 and the 200-day moving average was $95.35. A moving average is simply the average closing price over that number of trading days. The price is below the 50-day average and slightly above the 200-day average. The 50-day average is turning lower, while the 200-day average remains upward biased. The 50-day is still above the 200-day, which normally supports a positive long-term structure. I cannot confirm the exact date of the last crossover.

Relative strengthiHow this stock has performed against the wider market and against its own sector over the same period.

MIRM gained about 5.6% over six months, compared with about 18.0% for the biotech sector through 31 July 2026. Over 52 weeks, MIRM gained about 30.6%, while the biotech sector had gained about 72.4% through 31 July. MIRM is therefore lagging its sector. From 31 July to 28 August, MIRM fell 8.0%, while the biotech sector rose by roughly 10.5%. I cannot confirm the exact S&P 500 return over matching dates.

Volume trendiHow many shares are changing hands lately compared with normal. Heavy volume behind a move means more traders agree with it.

Twenty-day average volume was about 696,700 shares. Volume on 28 August was about 426,500 shares, or 61% of that average. The recent stabilization therefore occurred on light volume. This means fewer buyers supported the bounce than supported the heavy-volume selling after earnings.

VolatilityiHow much the share price swings day to day right now, compared with how much it usually swings.

Across the eight completed sessions from 19 through 28 August, the average daily high-to-low range was about $3.71, or 3.8% of the $97.00 current price. That is high trading volatility. You should use a smaller position than you would use in a stable large company. A stop placed only 1% away could be hit by ordinary daily movement.

Long-Term Technical ViewiThe wider chart over years. The big trend, the major price levels and how much the stock swings.

The multi-year trend remains positive. The stock rose from below $20 in 2022 to a record $130.00 in July 2026. Major long-term support sits near $80 to $85 and $63 to $70. The main long-term resistance is $120 to $130. Large corrections remain normal for this stock.

Technical biasiWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.

Neutral. The price is below the falling 50-day average, but it remains just above the rising 200-day average and has repeatedly held the $95 area. This is weaker than the positive catalyst call. I give the FDA outcome more weight for the event trade because a binary regulatory decision can overpower the chart.

What would invalidate this biasiThe price level or chart change that would prove the technical read wrong.

A regular-session close below $88.88 would invalidate the neutral view and make the chart bearish, with $80 to $85 becoming the next support area. A high-volume close above $107 would instead make the near-term structure bullish.

Technical data timestampiWhen the chart figures above were taken. Markets keep moving, so check live charts before you trade.

Price history, moving averages and completed-session volume data reflect the regular session through 28 August 2026, 20:00 UTC. Markets move after this report is written. Check live charts and current levels before placing any trade.

Stock OverviewiThe basic numbers. Price, size of the company, sector, the past year of highs and lows, trading volume and the next earnings date.

MIRM traded at $97.00 at 31 August 2026, 14:41:22 UTC. Market value was approximately $6.15 billion. Mirum operates in the healthcare sector and biotechnology industry. Its 52-week range was $63.23 to $130.00. Twenty-day average volume was about 696,700 shares. I cannot confirm the next scheduled earnings date.

What the company doesiThe business in plain words. What it sells, who buys it, and how the money reaches the company.

Mirum develops and sells medicines for rare diseases. Its main product, LIVMARLI, treats severe itching caused by rare inherited liver diseases. It also sells CHOLBAM and CTEXLI for rare bile-acid and metabolic disorders. Revenue mainly comes from prescription product sales. For example, when a diagnosed patient begins LIVMARLI treatment, Mirum records product revenue as medicine is supplied through specialty distribution channels.

Revenue BreakdowniWhere the money comes from, split by product, by part of the business and by country.

Second-quarter 2026 net product sales were $176.2 million. LIVMARLI produced $128.7 million, or 73.0%. The bile-acid medicines produced $47.5 million, or 27.0%. For the first half of 2026, LIVMARLI produced $242.5 million and bile-acid medicines produced $93.6 million. Mirum depends most on LIVMARLI. A slowdown in new LIVMARLI patients would have the largest effect on company growth. I cannot confirm a complete percentage split by country or region.

Company GrowthiHow sales, profit, earnings per share and spare cash have changed over the last few years.

Annual revenue was $77.1 million in 2022, $186.4 million in 2023, $336.9 million in 2024 and $521.3 million in 2025. That equals an approximate three-year compound annual growth rate of 89.1%. First-half 2026 product sales rose 40.4% to $336.1 million from $239.4 million a year earlier. Revenue growth is strong, but spending on acquisitions, research and commercialization has prevented steady profit and free-cash-flow growth. I cannot confirm a reliable full year-by-year series for net profit, earnings per share and free cash flow from the records reviewed.

Earnings PerformanceiThe latest results, whether they beat or missed what the market expected, and what the company says comes next.

Second-quarter 2026 product sales were $176.2 million, up 37.9% year over year. The quarter produced a net loss of $67.2 million, equal to about $1.07 per weighted-average share. I cannot confirm whether reported revenue or earnings per share beat the exact consensus estimates. Full-year 2026 net product sales guidance was raised to $680 million to $700 million from $660 million to $680 million. The raised guidance shows commercial momentum, although development and acquisition costs remain high.

Financial HealthiCash, debt, cash flow and profit margins, and whether the company keeps issuing new shares. Rated Strong, Average or Weak.

Mirum had $561.3 million of unrestricted cash, cash equivalents and investments at 30 June 2026. Total debt was approximately $763.0 million, implying net debt of about $201.7 million after including investments. Trailing operating cash flow was approximately negative $227.3 million and free cash flow was negative $228.7 million. Trailing gross margin was about 81.7%, while operating margin was negative 15.6%. Shares outstanding increased about 15.4% over one year. Mirum could likely survive one bad year without immediately raising equity, but continued heavy development spending would reduce that flexibility.

ValuationiWhat you pay today for what the company earns, next to its rivals and its own past. Rated Cheap, Fair or Expensive.

A meaningful price-to-earnings ratio, forward price-to-earnings ratio, PEG ratio and enterprise-value-to-EBITDA ratio were unavailable because earnings and EBITDA were negative. Price-to-sales was about 10.2 and forward price-to-sales was about 8.5. These ratios show how much investors pay today for each dollar of sales or earnings. I cannot confirm consistent competitor multiples using matching dates. The stock looks expensive because it carries a double-digit sales multiple despite negative free cash flow and execution risk.

ShareholdersiWho owns the company. Big funds, company insiders, and whether ownership sits with only a few holders.

Institutions held approximately 99.5% of outstanding shares, while insiders held about 1.3%. Janus Henderson held about 11.4%, BlackRock about 5.6%, and Vanguard about 4.0% in the latest confirmed disclosures. Ownership is highly institutional, but no single institution controls the company. Heavy institutional ownership can increase volatility when several funds change their position together.

Insider ActivityiWhether the people running the company have been buying or selling their own shares lately.

Executive Jolanda Howe reported an open-market sale of 40,000 shares at approximately $100.00 on 18 August 2026. I cannot confirm whether this transaction was made under a prearranged trading plan. The recent pattern appears weighted toward selling rather than open-market buying. Scheduled selling is a weaker negative signal than a discretionary sale, while an open-market purchase would be a stronger confidence signal.

Dividends and BuybacksiCash paid out to shareholders, whether that payment looks safe, and whether the company is buying back its own shares.

Mirum pays no dividend and has no confirmed active share-repurchase program. This is normal for a growth-focused biotechnology company investing in launches, acquisitions and clinical programs. The share count increased rather than declined, so shareholders have experienced dilution.

Competitive PositioniWho the company competes with, how much of the market it holds, and what it has that rivals do not.

Mirum has a commercial rare-disease infrastructure, four approved medicines, specialist relationships and experience finding patients with uncommon disorders. LIVMARLI competes with Ipsen's Bylvay in PFIC. Atebrioz competes with Regeneron's Pasatru and Ipsen's Sohonos in FOP. Mirum's advantage is its focused commercial organization and oral product portfolio; it can weaken if competitors show better efficacy, easier dosing, broader labels or lower prices.

Future OutlookiWhat sales and profit are expected to do next, and what management has promised.

Management expects 2026 product sales of $680 million to $700 million. Analysts expect continued revenue growth, with a three-year forecast rate near 25.5%, although forecasts can change. My view is positive on revenue growth because LIVMARLI and the acquired bile-acid medicines are expanding. Profitability is less certain because Mirum is funding several late-stage programs and recently took on substantial acquisition-related costs and debt.

Other Upcoming Company CatalystsiOther events ahead that could move the share price, such as results, launches or approvals, apart from the catalyst this report is built on.

The US launch of Atebrioz is planned for October 2026. Fourth-quarter 2026 catalysts include topline results from the LIVMARLI EXPAND Phase 3 study and the AZURE-1 and AZURE-4 brelovitug studies. VANTAGE Phase 2b results for volixibat in primary biliary cholangitis are expected in the first quarter of 2027, followed by a potential volixibat filing for primary sclerosing cholangitis in the first half of 2027.

Long-Term Company RisksiWhat could weaken the business over the coming years, rather than around this one event.

The main long-term risks are dependence on LIVMARLI, competition in small rare-disease markets, high drug prices facing payer resistance, negative free cash flow, debt, dilution, and expensive acquisitions that may not produce adequate returns. Clinical or regulatory failure in volixibat, brelovitug or other pipeline programs would reduce future growth expectations. The risk that concerns me most is paying a high valuation while development spending and debt prevent revenue growth from becoming durable free cash flow.

Traderavel VerdictiOur straight answer on the company after everything above, not on the trade. Quality, growth, price, risk and the long-term view.

Mirum is a strong commercial rare-disease business with high growth and a positive long-term outlook. Its approved portfolio and 2026 sales momentum separate it from a clinical-stage biotechnology company. Financial health is average because cash and growing sales are balanced by debt and negative free cash flow. Valuation is expensive. Long-term company risk is medium because the business depends heavily on a few rare-disease products and continued pipeline execution. The stock best suits risk-tolerant growth investors who can accept regulatory setbacks and large price swings. It does not suit income investors or investors who need predictable profits.